Patients receiving nirmatrelvir/ritonavir experience a quicker resolution of COVID-19 symptoms and are less likely to have worsened symptoms than those receiving placebo, a recent study shows.

Reimbursement authority NICE has backed the use of the two drugs as a first-line option for patients living with urothelial cancer (UC) – the most common form of bladder cancer – which has spread to ...

JAK inhibitors for rheumatoid arthritis demonstrate higher risks for cancer vs. biologic disease-modifying antirheumatic drugs, particularly among older patients and those with higher disease activity ...